Capital Impact Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-25,136
| Closed | -$489K | – | 169 |
|
|
2023
Q2 | $489K | Buy |
25,136
+11,529
| +85% | +$224K | 0.54% | 91 |
|
|
2023
Q1 | $386K | Buy |
13,607
+903
| +7% | +$25.6K | 0.47% | 97 |
|
|
2022
Q4 | $371K | Hold |
12,704
| – | – | 0.36% | 120 |
|
|
2022
Q3 | $465K | Buy |
12,704
+976
| +8% | +$35.7K | 0.46% | 86 |
|
|
2022
Q2 | $521K | Sell |
11,728
-4,190
| -26% | -$186K | 0.48% | 86 |
|
|
2022
Q1 | $788K | Sell |
15,918
-3,358
| -17% | -$166K | 0.57% | 71 |
|
|
2021
Q4 | $982K | Hold |
19,276
| – | – | 0.68% | 55 |
|
|
2021
Q3 | $1.08M | Hold |
19,276
| – | – | 0.43% | 97 |
|
|
2021
Q2 | $825K | Sell |
19,276
-16,539
| -46% | -$708K | 0.27% | 118 |
|
|
2021
Q1 | $1.5M | Hold |
35,815
| – | – | 0.52% | 72 |
|
|
2020
Q4 | $1.67M | Hold |
35,815
| – | – | 0.41% | 93 |
|
|
2020
Q3 | $1.52M | Hold |
35,815
| – | – | 0.45% | 90 |
|
|
2020
Q2 | $1.72M | Hold |
35,815
| – | – | 0.57% | 84 |
|
|
2020
Q1 | $1.65M | Buy |
35,815
+2,090
| +6% | +$96.1K | 0.69% | 67 |
|
|
2019
Q4 | $2.03M | Hold |
33,725
| – | – | 0.71% | 77 |
|
|
2019
Q3 | $1.9M | Sell |
33,725
-1,424
| -4% | -$80.4K | 0.73% | 79 |
|
|
2019
Q2 | $1.93M | Buy |
35,149
+1,210
| +4% | +$66.5K | 0.71% | 60 |
|
|
2019
Q1 | $1.33M | Hold |
33,939
| – | – | 0.59% | 98 |
|
|
2018
Q4 | $1.33M | Buy |
33,939
+9,855
| +41% | +$386K | 0.57% | 101 |
|
|
2018
Q3 | $1.66M | Hold |
24,084
| – | – | 0.57% | 99 |
|
|
2018
Q2 | $1.83M | Sell |
24,084
-2,233
| -8% | -$170K | 0.68% | 65 |
|
|
2018
Q1 | $1.39M | Buy |
+26,317
| New | +$1.39M | 0.57% | 92 |
|